|
オオメ ユウスケ
大目 祐介 所属 医学部 医学科（東京女子医科大学病院） 職種 助教 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma. |
| 掲載誌名 | 正式名：Annals of gastroenterological surgery 略 称：Ann Gastroenterol Surg ISSNコード：24750328/24750328 |
| 掲載区分 | 国内 |
| 巻・号・頁 | 7(2),pp.306-317 |
| 著者・共著者 | MATSUMURA Masaru, HONDA Goro, TANI Keigo, NAMOTO Satoshi, OME Yusuke, HAYAKAWA Sara, SUZUKI Mizuka, HORIGUCHI Shin-Ichiro, KIKUYAMA Masataka, SEYAMA Yasuji |
| 発行年月 | 2023/03 |
| 概要 | AIM:This study was performed to evaluate the efficacy of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 (S1-NACRT) for resectable pancreatic ductal adenocarcinoma.METHODS:The medical records of 132 patients who received S1-NACRT for resectable pancreatic ductal adenocarcinoma from 2010 to 2019 were reviewed. The S1-NACRT regimen consisted of S1 at a dose of 80-120 mg/body/day together with 1.8 Gy of radiation in 28 fractions. The patients were re-evaluated 4 weeks after S1-NACRT completion, and a pancreatectomy was then considered.RESULTS:Adverse events of S1-NACRT ≥grade 3 occurred in 22.7% of the patients, and 1.5% discontinued therapy. Of the 112 patients who underwent a pancreatectomy, 109 underwent R0 resection. Adjuvant chemotherapy with relative dose intensity ≥50% was administered to 74.1% of the patients who underwent resection. The median overall survival of all patients was 47 months, and the median overall survival and recurrence-free survival of patients who underwent resection was 71 and 32 months, respectively. According to the multivariate analyses of prognostic factors for overall survival in patients who underwent resection, negative margin status (hazard ratio: 0.182; P = 0.006) and relative dose intensity of adjuvant chemotherapy ≥50% (hazard ratio 0.294; P < 0.001) were independent prognostic factors of overall survival.CONCLUSIONS:A multidisciplinary approach incorporating S1-NACRT for resectable pancreatic ductal adenocarcinoma demonstrated acceptable tolerability and good local control and resulted in comparable survival benefits. |
| DOI | 10.1002/ags3.12624 |
| PMID | 36998294 |